BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 22, 2022 07:30 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification
April 04, 2022 08:00 ET
|
BioRestorative Therapies, Inc
Certification Gives BioRestorative Therapies Clinical Grade Manufacturing Capabilities MELVILLE, N.Y., April 04, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or...
BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program
February 16, 2022 08:30 ET
|
BioRestorative Therapies, Inc
Notice of Allowance Grants Protection for BioRestorative’s Phase 2 Clinical Program to Treat Chronic Lumbar Disc Disease MELVILLE, N.Y., Feb. 16, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies,...
BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway
February 07, 2022 09:00 ET
|
BioRestorative Therapies, Inc
BioRestorative Provides Update on its Active Phase 2 Clinical Trial MELVILLE, N.Y., Feb. 07, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:...
BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell
February 07, 2022 07:45 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Feb. 07, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
February 02, 2022 08:00 ET
|
BioRestorative Therapies, Inc
Notice of Allowance Grants Protection for Generating Implantable Three-Dimensional Scaffolds MELVILLE, N.Y., Feb. 02, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or...
BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show
December 21, 2021 06:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program
December 02, 2021 06:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 02, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program
September 23, 2021 09:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Sept. 23, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today...
BioRestorative Therapies Receives Patent in Australia Related to its Off-the-Shelf ThermoStem® Program
September 02, 2021 09:00 ET
|
BioRestorative Therapies, Inc
Issued Patent Grants Protection for an Implantable Scaffold using Brown Adipose Derived Stem Cells and Methods of Use MELVILLE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies,...